21:30 , Mar 11, 2019 |  BC Extra  |  Company News

Seres, AZ partner on microbiome research to treat cancer, predict response

Seres gained $1.27 (25%) to $6.38 on Monday after it announced a three-year partnership with AstraZeneca to evaluate microbiome-based approaches to improve and predict patient response to immunotherapies. Seres Therapeutics Inc. (NASDAQ:MCRB) will receive $20...
00:15 , Mar 9, 2019 |  BC Extra  |  Clinical News

Jounce seeking tumor-agnostic approach for ICOS agonist

Jounce said the ICOS hi CD4 T cells biomarker could allow the company to take a tumor-agnostic approach for its ICOS agonist vopratelimab (JTX-2011) to select patient populations more likely to respond to the therapy....
22:36 , Mar 5, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting NR4A1, NR4A2 and N4RA3 in CAR Ts to enhance efficacy in solid tumors

DISEASE CATEGORY: Cancer INDICATION: Melanoma; colorectal cancer Mouse studies suggest inhibiting NR4A1, NR4A2 and NR4A3 in CAR T cells could enhance the cells' efficacy in melanoma, colorectal cancer and other solid tumor types. In CD8+...
23:09 , Feb 26, 2019 |  BC Extra  |  Company News

CytomX R&D day reveals Probody toxicity, chopped BMS deal

CytomX Therapeutics Inc. (NASDAQ:CTMX) lost $6.03 (32%) to $13.13 on Tuesday after reporting severe toxicity signals with its CD166 Probody-drug conjugate, and disclosing that partner Bristol-Myers Squibb Co. (NYSE:BMY) terminated three targets under their discovery...
04:45 , Feb 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Solid checkpoint for CARs

PD-L1 family member B7-H3 could put CAR T cells in play for a slew of difficult-to-treat solid tumors, including pediatric cancers that lack targeted therapies, according to a pair of preclinical studies published this year....
20:16 , Feb 21, 2019 |  BC Innovations  |  Emerging Company Profile

Refuge: Receptive CAR checkpoints

Refuge Biotechnologies Inc. aims to make CAR T cells more potent by suppressing their checkpoint genes and is using a form of CRISPR that knocks the genes down instead of out to improve safety. CEO...
22:45 , Feb 14, 2019 |  BC Extra  |  Company News

MedImmune vanishes as AZ restructures, returns to growth

AstraZeneca plc (LSE:AZN; NYSE:AZN) recorded its first year of product sales growth since 2009 and unveiled a new R&D structure in its 2018 earnings report Thursday. With the restructuring, AZ will drop the MedImmune unit...
13:25 , Feb 8, 2019 |  BioCentury  |  Emerging Company Profile

Palleon: Sweeter checkpoints

With two platforms targeting glycan ligands and their receptors, and a third to match cancer patients to a therapy, Palleon Pharmaceuticals Inc. aims to treat cancer by removing the brakes on a class of checkpoints...
16:04 , Feb 5, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; melanoma; cancer Mouse studies suggest an mRNA immunotherapy based on IL-36γ, IL-23 and OX40L could help treat colorectal cancer, melanoma and other cancers, including those resistant to checkpoint inhibitors. The therapy consists...
19:52 , Feb 1, 2019 |  BC Week In Review  |  Financial News

Agenus to sell blockchain tokens to fund PD-1 development

Agenus Inc. (NASDAQ:AGEN) said Jan. 29 that is seeking to raise up to $100 million via the sale of blockchain-powered tokens tied to clinical anti-PD-1 mAb AGEN2034. The company said the asset-backed digital security is...